|

tabelecleucel Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: ATA129, EBV-CTL, EBV-CTLs, Ebvallo®, tab-cel®

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Pierre Fabre Medicament2

Indications

  • Allogeneic Hematopoietic Cell Transplant2
  • Lymphoproliferative Disorders2
  • Solid Organ Transplant Complications2
  • Stem Cell Transplant Complications2
  • Cancer2

Duarte, California1 trial

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

City of Hope (Adults and Pediatrics)

Phase 3

Los Angeles, California1 trial

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

University of California Los Angeles (UCLA) (Adults and Pediatrics)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.